Le Lézard
Classified in: Health, Business, Covid-19 virus
Subjects: ERN, TRI

Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results


Preliminary dose escalation data expected in second half of 2022 from the ARROS-1 study of NVL-520 for advanced ROS1 positive NSCLC and other solid tumors

Rapid advancement of pipeline with clinical trials ongoing for NVL-520 and NVL-655 and two additional development candidates on-track for selection in 2022

CAMBRIDGE, Mass., Aug. 10, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today reported pipeline progress and second quarter 2022 financial results.

"Our focus for 2022 is on execution across our pipeline of novel kinase inhibitors, and the Nuvalent team has continued to deliver. In the past quarter, we announced our plan to share preliminary dose escalation data in the second half of 2022 from the Phase 1 portion of our Phase 1/2 ARROS-1 trial for patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors, and dosed the first patient in our Phase 1/2 ALKOVE-1 trial for patients with advanced ALK-positive NSCLC and other solid tumors," said James Porter, Ph.D., Chief Executive Officer at Nuvalent. "Additionally, we've continued to advance our discovery pipeline and remain poised to nominate two additional development candidates by the end of this year ? a testament to the strength, ingenuity, and efficiency of the Nuvalent team, our capabilities, and approach. This is an exciting time for our company, and I'm confident in our ability to deliver on our goal of precisely targeted therapies that can enable deep and durable responses for patients with cancer."

Recent Pipeline Achievements and Anticipated Near-Term Milestones
Second Quarter 2022 Financial Results
About Nuvalent

Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), along with multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at www.nuvalent.com. Follow us on Twitter (@nuvalent) and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Nuvalent's strategy, business plans, and focus; the clinical development programs for NVL-520, NVL-655, ALK IXDN compound resistance mutations and HER2 Exon 20 insertions and the timing thereof; the potential clinical effect of NVL-520 and NVL-655; the design and enrollment of the ARROS-1 and ALKOVE-1 studies and the timing thereof; the potential of Nuvalent's pipeline programs, including NVL-520 and NVL-655; Nuvalent's research and development programs for the treatment of cancer; risks and uncertainties associated with drug development; and capital allocation. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "aim," "goal," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" or the negative of these terms and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. You should not place undue reliance on these statements or the scientific data presented.

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: risks that Nuvalent may not fully enroll the ARROS-1 or ALKOVE-1 studies or that enrollment will take longer than expected; unexpected concerns that may arise from additional data, analysis, or results obtained during clinical trials; the occurrence of adverse safety events; risks of unexpected costs, delays, or other unexpected hurdles; risks that Nuvalent may not be able to nominate drug candidates from its HER2 Exon 20 and ALK IXDN programs; the direct or indirect impact of COVID-19 or other global geopolitical circumstances on the timing and anticipated timing and results of Nuvalent's clinical trials, strategy, and future operations, including the ARROS-1 and ALKOVE-1 studies; the timing and outcome of Nuvalent's planned interactions with regulatory authorities; and obtaining, maintaining, and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Nuvalent's views only as of today and should not be relied upon as representing its views as of any subsequent date. Nuvalent explicitly disclaims any obligation to update any forward-looking statements.

 

SELECTED STATEMENTS OF OPERATIONS DATA


(In thousands, except share and per share data)


(Unaudited)



















Three Months Ended June 30,



Six Months Ended June 30,




2022



2021



2022



2021


Operating expenses:

















Research and development


$

13,558



$

7,826



$

26,251



$

13,310


General and administrative



5,175




2,024




10,170




2,702


Total operating expenses



18,733




9,850




36,421




16,012


Loss from operations



(18,733)




(9,850)




(36,421)




(16,012)


Other income (expense):

















Change in fair value of preferred stock

   tranche rights



?




?




?




(635)


Other income, net



267




12




406




24


Total other income (expense), net



267




12




406




(611)


Net loss


$

(18,466)



$

(9,838)



$

(36,015)



$

(16,623)


Net loss per share attributable to

   common stockholders, basic and diluted


$

(0.38)



$

(3.17)



$

(0.75)



$

(5.37)


Weighted average shares of common stock

   outstanding, basic and diluted



48,319,067




3,106,152




48,302,017




3,095,639


 

SELECTED BALANCE SHEET DATA


(In thousands)


(Unaudited)













June 30,



December 31,




2022



2021


Cash, cash equivalents and marketable securities


$

256,964



$

288,111


Working capital


$

248,786



$

281,841


Total assets


$

263,021



$

293,824


Total liabilities


$

10,036



$

8,787


Total stockholders' equity


$

252,985



$

285,037


 

SOURCE Nuvalent, Inc.


These press releases may also interest you

at 16:54
Royal Bank of Canada today announced a donation of $250,000 to the Red Cross Hurricane Fiona in Canada Appeal to support people across eastern Canada who have been impacted by this devastating hurricane....

at 15:48
Desjardins Group will quickly set up support measures for members and clients affected by Hurricane Fiona. It has also teamed up with the Canadian Red Cross, making a $75,000 donation to the Hurricane Fiona in Canada Appeal relief fund. "It's...

at 14:42
Scotiabank is donating $250,000 to the Canadian Red Cross to get urgent relief to those in Eastern Canada affected by Hurricane Fiona. Funding will also support long-term recovery and resiliency efforts in the communities most impacted....

24 sep 2022
Three social change organizations are partnering on a new and unique approach to philanthropy by funding and advancing digital equity advocacy in California...

24 sep 2022
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at...

24 sep 2022
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Stitch Fix, Inc. between December 8, 2020 and March 8, 2022, both dates inclusive (the "Class Period"), of the important October 25, 2022 lead plaintiff...



News published on 10 august 2022 at 06:30 and distributed by: